{"groups":[{"description":"Patients receive gemcitabine IV over 30 minutes followed by docetaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.\n\nGemcitabine Hydrochloride: Given IV\n\nDocetaxel: Given IV","id":"FG000","title":"Treatment (Gemcitabine Hydrochloride, Docetaxel)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Wrong Cell Type"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Wrong Primary"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Never Treated"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"28"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"24"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"This trial was opened to patient entry on March 7, 2005 and was closed to accrual on October 29, 2007"}